Solid Tumors
Conditions
Keywords
Solid tumors
Brief summary
The primary objective of this study is to determine the safe and tolerable dose level of OPB-111077 for patients with advanced cancer.
Detailed description
The secondary objective of this study is to investigate the pharmacokinetic properties of OPB-111077; the pharmacodynamic effects of OPB-111077; the antitumor activity of OPB-111077 as assessed by RECIST or IMWG Uniform Response Criteria; and to explore whether PET responses correlate with other measures of clinical response.
Interventions
DRUGOPB-111077
Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops. Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles.
Sponsors
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically and/or cytologically confirmed advanced malignancy that is refractory to standard therapy or for which there are no standard treatment options available * For oral or intravenous anticancer therapies, at least 4 weeks or 5 half-lives, whichever is shorter, need to have elapsed since the last dose * Recovery from adverse effects of prior therapy at time of enrollment to o ≤ Grade 1 (excluding alopecia) * Agreement to forego any other chemotherapy, immunotherapy, radiotherapy, or investigational drug while enrolled on this trial except hormonal therapy for prostate cancer or radiotherapy for symptomatic bone metastases known to be present at Screening * Male or female subjects aged ≥ 18 years * ECOG performance status ≤ 2 * Adequate organ function * Life expectancy of ≥ 3 months following trial entry * For women of childbearing potential, a negative serum pregnancy test result at Screening * For women of childbearing potential or men whose sexual partners are women of childbearing potential, agreement to use 2 methods of adequate contraception prior to trial entry, for the duration of the trial, and for 90 days after the last dose of trial medication * Signed and dated IRB-approved informed consent prior to any performance of protocol-specific screening procedures
Exclusion criteria
* Uncontrolled concurrent illness, including but not limited to: ongoing or active infection; uncontrolled heart, liver, kidney, or endocrine disorder * Altered mental status, psychiatric illness, or social situation that would limit compliance with trial requirements and/or obscure trial results * Immunocompromised state * Known or evidence of chronic viral hepatitis (hepatitis B or C virus) * Untreated or symptomatic brain metastasis, or subjects with leptomeningeal disease * Inability to swallow oral meds or gastrointestinal disorder that might interfere with absorption of oral drugs * Major surgery within 28 days of first receipt of trial drug * Nursing or pregnant women * ≥ Grade 1 neuropathy with pain or \> Grade 2 neuropathy without pain (subjects with neuropathy caused by a previous regimen that is recovered to ≤ Grade 2 and stable without pain may be included) * Food-effect sub-study (Part B) only: Pathologies or medical histories that might impair absorption and elimination. * PET scan sub-study (Part C) only: Uncontrollable blood glucose or intolerance to PET scan procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability of OPB-111077 | 28 Days | AEs, Vital signs,Body weight, ECGs, Laboratory tests, Performance status |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacodynamic profile | 28 Days | Study drug effects on STAT3 phosphorylation in response to IL-6 will be measured in PBMCs from subjects treated with OPB-111077. |
| Antitumor effects | Assessments will be conducted at Screening, Cycle 3, every 2 cycles (+/- 1 week) thereafter, at the Final/Early Termination Visit, and at the 30-day Follow-up Visit. | Subjects with measurable disease will be assessed by RECIST Assessments will be conducted at Screening, Cycle 3, every 2 cycles (+/- 1 week) thereafter, at the Final/Early Termination Visit, and at the 30-day Follow-up Visit. |
| To determine the pharmacokinetics of OPB-111077 | 28 Days | The following PK parameters for Food-effect Sub-study (Cmax, AUCtau,AUCt, tmax, CLss/F and t1/2,z) will be determined using a non-compartmental approach for OPB-111077 and selected metabolites after single (Cycle 1, Day 1) and multiple daily doses (Cycle 2, Day 1). |
| PET Sub-study (Part C) | 2 weeks | A sub-study of up to 24 patients with PET-avid tumors where additional PET scans are performed to explore intra-subject PET activity. |
| Food-effect Sub-study (Part B) | 11 days | An open-label, two-period crossover arm, for pre-selected study sites to determine the effect of food on the rate and extent of absorption (PK) following single dose 250mg OPB-111077. |
| To determine the MTD of OPB-111077 | Within the first cycle [28 days]. | The highest dose at which fewer than 2 of 6 subjects experience DLT during the first 28 day cycle. |
Countries
United States
Outcome results
None listed